A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.